In England, EP training is being squeezed by the need for dual accreditation in general internal medicine.
We argue that this risks a generation of underprepared specialists.
Our article in AER : https://t.co/xx4WVIVmLp
@tom__slater@drashnisbet@DhirajGuptaBHRS@johnpaisey
Reminds of this slide I have shown over the years of genes harboring (human) mutations conferring resistance to MI and ASCVD
These targets getting a lot of attention.
Great to see @TheBHF supporting screening programmes for important diseases. Screening often attracts criticism in resource-poor systems, but FIND-AF shows a potential way to reduce devastating strokes from an often asymptomatic disease.
📢 Late-Breaking at #ESC2025: FIND-AF clinical trial (n≈2,000)
➡️ Machine learning–guided screening identifies a subgroup with 8-fold higher risk of AF among patients at elevated stroke risk.
💡 AI could transform early AF detection
@TheBHF @LeedsHospCharity @NIHRresearch
@DevanSinha@AAMortazavi Except this paper does assess NYHA class (metoprolol loses) and, crucially, the primary end point was an objective measure of exercise capacity.
My point was more the biotechbros focusing on the least patient-relevant outcome. But what do I know?!